Russell Investments Group
KNTE

Russell Investments Group’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Russell Investments Group’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-631
Closed -$1.91K – 3653
2023
Q2 		$1.91K Buy
+631
New +$2.43K ﹤0.01% 3250
2023
Q1 		– Sell
-955
Closed -$5.83K – 3417
2022
Q4 		$5.83K Hold
955
– – ﹤0.01% 2860
2022
Q3 		$11K Buy
+955
New +$12.5K ﹤0.01% 2859
2022
Q1 		– Sell
-55,568
Closed -$984K – 2983
2021
Q4 		$984K Buy
55,568
+33,113
+147% +$698K ﹤0.01% 2154
2021
Q3 		$516K Buy
+22,455
New +$489K ﹤0.01% 2449

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Russell Investments Group's KNTE Position: Q3 2023 in Review

Russell Investments Group sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q3 2023, closing a stake of 631 shares — an estimated $1.91K sold.

Russell Investments Group first reported a position in KNTE in Q3 2021 and held it in 5 quarters. The position peaked at $984K in Q4 2021. 58 funds tracked by Wall St. Rank hold KNTE as of Q3 2023.

  • Russell Investments Group reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Russell Investments Group sold 631 Kinnate Biopharma Inc. Common Stock shares in Q3 2023, an estimated $1.91K.
  • Russell Investments Group first reported a position in Kinnate Biopharma Inc. Common Stock in Q3 2021 and held it in 5 quarters.
  • Russell Investments Group's Kinnate Biopharma Inc. Common Stock position peaked at $984K in Q4 2021.
  • 58 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q3 2023.

Based on Russell Investments Group's 13F filing for Q3 2023, filed 13 Nov 2023.